Approved by at least one major regulator for a defined indication, with published human pharmacokinetics and a prescribing label. Well-characterised does not mean risk-free, read the label warnings.
Minutes, not hours: mean elimination half-life 18.6 min after a single subcutaneous injection and 37.8 min after multiple injections (11 min reported for Egrifta WR at 1.28 mg). Median tmax 0.15 h. The extremely short half-life is the point, tesamorelin triggers a pulse of endogenous GH release rather than sustaining a level.
Model a dosing schedule →Label doses: 2 mg daily (Egrifta/Egrifta SV) and 1.28 mg daily (Egrifta WR). Formulations are not interchangeable.
Lyophilised: See label, varies by formulation (Egrifta SV and WR differ).
Reconstituted: Use promptly after reconstitution per label instructions.
Contraindicated in pregnancy and in active malignancy. Increases IGF-1, label advises monitoring. Risks include glucose intolerance and diabetes, fluid retention, arthralgia, injection-site reactions, and hypersensitivity. Contraindicated with disruption of the hypothalamic-pituitary axis.